Skip to content

Buzhong Tiaogan Formula for delaying colorectal liver metastasis (liver depression spleen deficient type): a multicenter randomized controlled trial

Buzhong Tiaogan Formula for delaying colorectal liver metastasis (liver depression spleen deficient type): a multicenter randomized controlled trial

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100050757
Enrollment
Unknown
Registered
2021-09-04
Start date
2021-10-01
Completion date
Unknown
Last updated
2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal liver metastasis

Interventions

Sponsors

Shanxi Provincial Hospital of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years, survival period >= 6 months; 2. Patients with colorectal cancer and no liver metastasis (spleen deficiency and liver stagnation type) who meet the above-mentioned diagnostic criteria of western medicine and traditional Chinese medicine and have been diagnosed by definite pathology or cytology; 3. Those who have not taken traditional Chinese medicine in the past 1 month and received chemotherapy; 4. No other primary tumors and serious heart, liver and kidney diseases; 5. Those who have follow-up telephone numbers and addresses, patients or their families who are willing to cooperate with follow-up visits, have relatively complete medical records, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Non-primary colorectal cancer; 2. Those who are unable or unwilling to accept traditional Chinese medicine treatment; 3. The patient has developed intestinal obstruction and cannot take drugs, needs intravenous high-energy nutrition, or has malabsorption syndrome or other diseases that affect the absorption of the gastrointestinal tract, or has active peptic ulcer disease.

Design outcomes

Primary

MeasureTime frame
Quality of Life;the time of occurrence of liver metastasis;TCM Symptom Score;no disease progression;overall survival;

Secondary

MeasureTime frame
Card-style functional status score;size of tumor;tumor marker;tumor microenvironment;immune state;

Countries

China

Contacts

Public ContactWang Xixing

Shanxi Provincial Hospital of Traditional Chinese Medicine

wangxx315@163.com+86 13509735661

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026